1. Home
  2. PANW vs REGN Comparison

PANW vs REGN Comparison

Compare PANW & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Palo Alto Networks Inc.

PANW

Palo Alto Networks Inc.

HOLD

Current Price

$186.91

Market Cap

143.7B

Sector

Technology

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$765.73

Market Cap

73.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PANW
REGN
Founded
2005
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
143.7B
73.9B
IPO Year
2012
1991

Fundamental Metrics

Financial Performance
Metric
PANW
REGN
Price
$186.91
$765.73
Analyst Decision
Buy
Buy
Analyst Count
40
23
Target Price
$224.00
$795.74
AVG Volume (30 Days)
6.8M
1.1M
Earning Date
11-19-2025
02-03-2026
Dividend Yield
N/A
0.46%
EPS Growth
N/A
2.88
EPS
1.58
41.59
Revenue
$9,556,500,000.00
$14,247,800,000.00
Revenue This Year
$16.46
$1.95
Revenue Next Year
$13.25
$5.47
P/E Ratio
$118.28
$18.46
Revenue Growth
15.30
2.89
52 Week Low
$144.15
$476.49
52 Week High
$223.61
$790.98

Technical Indicators

Market Signals
Indicator
PANW
REGN
Relative Strength Index (RSI) 40.82 64.36
Support Level $183.19 $739.23
Resistance Level $188.33 $757.35
Average True Range (ATR) 4.34 19.21
MACD -0.04 -1.25
Stochastic Oscillator 23.70 98.42

Price Performance

Historical Comparison
PANW
REGN

About PANW Palo Alto Networks Inc.

Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: